3 unchanged sentences
Replimune Group, Inc.
−Removed: 1:25-cv-12085-JEK, was filed shortly after the Company announced it received a complete response letter from the FDA for its RP1 BLA for the treatment of advanced melanoma on July 22, 2025 and the subsequent decline in the trading price of the Company's common stock.
−Removed: The Court is in the process of appointing a lead plaintiff.
+Added: 1:25-cv-12085-JEK, was filed shortly after the Company announced it received a complete response letter, or CRL, from the FDA for its RP1 BLA for the treatment of advanced melanoma on July 22, 2025 and the subsequent decline in the trading price of the Company's common stock.
+Added: The Court has appointed a lead plaintiff, or the Lead Plaintiff.
+Added: O n January 13, 2026, Lead Plaintiff filed an amended complaint.
The Company and the other defendants deny any wrongdoing and will vigorously defend this action.
4 unchanged sentences
The plaintiffs allege substantially similar facts as the class action complaint and assert that the Company’s directors and officers breached their fiduciary duties.
−Removed: The parties are in the process of consolidating the derivative actions and negotiating a stay pending further developments in the class action.
−Removed: On September 10, 2025, the Company received a letter from a shareholder demanding that the Board of Directors take action to address alleged wrongdoing by certain directors and officers.
+Added: The parties have consolidated the derivative actions and agreed to a stay pending further developments in the class action.
+Added: On September 10, 2025, the Company received a letter from a shareholder demanding that the Company's board of directors take action to address alleged wrongdoing by certain directors and officers.
The demand letter alleged substantially similar facts as the class action and derivative action complaints.
−Removed: The Board determined to defer action on the demand pending further developments in the class action.
+Added: The board of directors determined to defer action on the demand pending further developments in the class action.
On September 29, 2025, the U.S.
1 unchanged sentence
The investigation is reviewing essentially the same subject matter raised in the litigation following the CRL.
−Removed: The Company intends to cooperate with the SEC’s investigation and provide the requested materials.
+Added: The Company is cooperating with the SEC’s investigation and providing the requested materials.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.